Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States
Go back to Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 466.58 -0.21 (0.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $466.79 | 52 Week High | $134.71 | |||
| Open | $469.67 | 52 Week Low | $73.31 | |||
| Day High | $470.76 | P/E | N/A | |||
| Day Low | $463.76 | EPS | $-1.98 | |||
| Volume | 194,847 | |||||
